Speedometer Blog

Friday, July 23, 2021
While businesses return to full capacity and mask mandates are lifted in much of the US and several other countries with relatively high vaccination rates, there is growing concern about the impact from the rapidly spreading COVID-19 delta variant.
Friday, July 16, 2021
Of the 3.5 billion COVID-19 vaccine doses that have been administered globally, only about 69 percent of the doses have been administered in low and middle income countries (LMICs) with 84 percent of the world’s population. Wealthy nations’ over-purchasing of the limited vaccine supply left LMIC nations without access to COVID-19 vaccine doses.
Friday, July 9, 2021
Many countries in Africa, Asia, and Latin America have yet to receive the vaccines necessary to slow the spread of Covid-19 despite recent purchase and donation agreements. In recent weeks, large scale donations of Covid-19 vaccines have made headlines as the US and EU promised to send hundreds of millions of doses to low- and middle-income countries (LMICs).
Friday, July 2, 2021
We are excited to release new data this week, tracking vaccine donations by donor country, recipient (cut by continent and income category), and vaccine. Our data include doses that have been pledged, regardless of whether they have already been delivered. The interactive visualizations show which countries are the big donors, which vaccines are being donated, and where they are going.
Friday, June 18, 2021
The G7 began their much-anticipated summit last week with a target to reach 1 billion doses of Covid-19 vaccine in pledged donations for low- and middle-income countries (LMICs). The result could be described as underwhelming (as well as unclear).
Friday, June 11, 2021
Starting mid-March 2021, India has become the epicenter of COVID-19 as a second wave of infections devastated the country. India reported 50 percent of global cases and 30 percent of global COVID-19 deaths, and an alarming rate of over 400,000 daily new cases at the height of the wave in early May 2021.
Friday, June 4, 2021
Multiple COVID-19 genetic variants have been detected since the initial SARS-CoV-2 strain was found in China, the most significant of which are classified by the WHO as variants of concern or variants of interest, depending on their attributes and risk level.
Friday, May 28, 2021
According to Our World in Data, 1.78B people are fully vaccinated against COVID-19 across the world. About 16% of the fully vaccinated (289M people) live in the US, which has a very high rate of vaccination, especially compared to neighboring countries in Latin America.
Friday, May 21, 2021
The G20 met today in Rome for a Global Health Summit and vaccine equity was at the top of the agenda. According to Reuters, the resulting “Rome Declaration” calls for voluntary licensing and technology transfers to increase production of Covid-19 vaccines globally. The declaration also reportedly mentioned the important role of the ACT-Accelerator (of which COVAX is one pillar) but did not commit to funding it (the ACT-Accelerator still needs $19 billion to reach its goal).
Saturday, May 15, 2021
Manufacturing projections for Covid-19 vaccines seem to shift on a near-weekly basis. We are not even halfway into 2021 and already we have seen adjustments, both up and down, across all vaccine makers.
Friday, May 7, 2021
The US threw its weight into the ring on the side of the TRIPS waiver this week, surprising many. There is still a long road ahead for the waiver, which much be agreed through discussion and consensus. With vocal opponents (including Germany), this is unlikely to happen before December. But if it does go through and intellectual property (IP) protections are waived, will it make a difference?
Monday, May 3, 2021
There is a lot of ground to cover this week. The pandemic continues to rage throughout the world, with countries in South Asia and Latin America battling the worst surges. India has set new world records for daily infections and deaths, while eschewing a nation-wide lockdown and struggling to implement a mass vaccination campaign with limited supply.
Friday, April 23, 2021
Launched as a global cross-organization collaboration only one month after the pandemic was declared, COVAX was built to facilitate global equity in the pandemic response. As COVAX passes the one-year mark this month, there are some early lessons and insights that can inform its further development and help us prepare for future crises.
Friday, April 16, 2021
COVID-19 vaccines across the world have been produced and authorized for use with record speed. So far, 13 vaccines have received either limited or full regulatory approval. It’s important to note that the safety of the vaccines is continuously monitored even after limited and full regulatory approvals are granted.
Friday, April 9, 2021
A promising new vaccine candidate is getting a flurry of attention this week, even in a very crowded landscape that includes 11 vaccines on the market and 50+ more in Phase 2 or 3 trials. The newcomer NDV-HXP-S vaccine, developed through collaborations between researchers at University of Texas at Austin, PATH, and Mount Sinai, among others, is a mouthful to say but the name captures the two reasons people are excited about it.